New Hampshire 2022 Regular Session

New Hampshire House Bill HB381

Introduced
1/10/21  
Refer
1/10/21  
Report Pass
3/11/21  
Report DNP
3/11/21  
Engrossed
4/13/21  
Refer
4/13/21  
Refer
5/13/21  
Refer
5/20/21  
Report Pass
12/16/21  
Enrolled
6/14/22  
Chaptered
6/28/22  

Caption

Relative to laboratory testing.

Impact

The passage of HB 381 is expected to impact state laws regarding healthcare access by enhancing patient autonomy over medical testing. By enabling direct access to laboratory tests, this bill may promote early detection and treatment of conditions, as individuals can pursue relevant testing without navigating the traditional healthcare provider referral pathways. However, it also raises questions about the implications for patient safety and the quality of care, as individuals may receive test results without professional guidance on interpretation and next steps.

Summary

House Bill 381 aims to authorize laboratory testing without the prior request or authorization of a licensed medical practitioner. This legislative change is significant as it allows individuals to obtain laboratory tests directly from clinical laboratories that offer such tests on a public access basis. The bill adds new rulemaking authority for the Department of Health and Human Services to ensure proper guidelines and standards are maintained within the laboratories performing these tests. The implementation of this bill is set to take effect on January 1, 2023.

Sentiment

Public and legislative sentiment surrounding HB 381 appears to be mixed. Supporters, particularly those advocating for increased patient choice and autonomy, view the bill as a positive development in enhancing access to healthcare. Conversely, there are concerns from some healthcare professionals regarding the potential risks of patients conducting tests without medical oversight, which could lead to misinterpretation of results and unnecessary anxiety or missed diagnoses. This dichotomy reflects a broader debate about the balance between patient independence and the necessity for Professional medical management.

Contention

Notable points of contention include the responsibilities of medical practitioners and the financial implications for laboratories under this new framework. The bill explicitly states that practitioners are not liable for tests they did not authorize, which could be perceived as relieving them of necessary oversight in patient care. Additionally, the prohibition against laboratories submitting claims for tests performed without authorization could impact the financial viability of these testing services and influence how they are covered by insurance policies. The combined effect of these aspects has led to a thorough examination of the implications for both healthcare practice and patient experiences.

Companion Bills

No companion bills found.

Previously Filed As

NH AB2107

Clinical laboratory testing.

NH SB348

Makes revisions relating to laboratory testing. (BDR 40-123)

NH HB262

Relative to laboratory testing by licensed naturopaths

NH H2395

Relative to clinical laboratories

NH H3628

Relative to clinical laboratories

NH SB120

Relative to insurance coverage for biomarker testing.

NH SB962

Healing arts: clinical laboratory technology: moderate-complexity laboratories.

NH HB1642

Relative to lead testing in children.

NH AB1461

Cannabis: testing laboratories.

NH AB1458

Cannabis testing laboratories.

Similar Bills

CA AB2107

Clinical laboratory technology: remote review.

CA SB962

Healing arts: clinical laboratory technology: moderate-complexity laboratories.

CA SB1267

Clinical laboratories.

CA AB526

Dentists and podiatrists: clinical laboratories and vaccines.

CA SB409

Pharmacy practice: testing.

CA AB3009

Hazardous materials: lead-based paint.

CA AB2281

Clinical laboratories: licensed medical laboratory technicians.

CA AB1741

Healing arts: clinical laboratories: personnel.